Evaluate the side effect associated with COVID-19 vaccine on adolescents in Riyadh, Saudi Arabia

References

1. 1.↵
   1. Hong KH,
   2. Lee SW,
   3. Kim TS,
   4. Huh HJ,
   5. Lee J,
   6. Kim SY, et al.

   Guidelines for laboratory diagnosis of coronavirus disease 2019 (COVID-19) in Korea. Ann Lab Med 2020; 40: 351–360.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Mesev EV,
   2. LeDesma RA,
   3. Ploss A.

   Decoding type I and III interferon signalling during viral infection. Nat Microbiol 2019; 4: 914–924.

   OpenUrl
3. 3.↵
   1. Cucinotta D,
   2. Vanelli M.

   WHO declares COVID-19 a pandemic. Acta Biomed 2020; 91: 157.

   OpenUrl
4. 4.↵
   1. Alhazmi A,
   2. Alamer E,
   3. Daws D,
   4. Hakami M,
   5. Darraj M,
   6. Abdelwahab S, et al.

   Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia. Vaccines (Basel) 2021; 9: 674.

   OpenUrl
5. 5.↵
   1. Mascellino MT,
   2. Di Timoteo F,
   3. De Angelis M,
   4. Oliva A.

   Overview of the main anti-SARS-CoV-2 vaccines: mechanism of action, efficacy and safety. Infect Drug Resist 2021; 14: 3459.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Meo S,
   2. Bukhari I,
   3. Akram J,
   4. Meo A,
   5. Klonoff DC.

   COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci 2021: 1663–1669.
7. 7.↵
   1. Anderson EJ,
   2. Rouphael NG,
   3. Widge AT,
   4. Jackson LA,
   5. Roberts PC,
   6. Makhene M, et al.

   Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427–2438.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Adam M,
   2. Gameraddin M,
   3. Alelyani M,
   4. Alshahrani MY,
   5. Gareeballah A,
   6. Ahmad I, et al.

   Evaluation of post-vaccination symptoms of two common COVID-19 vaccines used in Abha, Aseer Region, Kingdom of Saudi Arabia. Patient Prefer Adherence 2021;15: 1963-1970.
9. 9.↵
   Public Health Authority. Interim guidelines for the use of SARS-CoV-2 vaccine. [Updatyed 2021 Aug 31; Accessed date?]. Available from: https://covid19.cdc.gov.sa/professionals-health-workers/interim-guidelines-for-the-use-of-sars-cov-2-vaccine/
10. 10.↵
    1. Frenck Jr RW,
    2. Klein NP,
    3. Kitchin N,
    4. Gurtman A,
    5. Absalon J,
    6. Lockhart S, et al.

    Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med 2021; 385: 239–250.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Hause AM,
    2. Gee J,
    3. Baggs J,
    4. Abara WE,
    5. Marquez P,
    6. Thompson D, et al.

    COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 1053–1058.

    OpenUrlCrossRefPubMed